相关实验视频

Updated: May 17, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

针对CHEK2-YBX1&YBX3监管枢纽,以加强质瘤中的免疫检查点阻塞反应

Heba Ali, Ningjia Zhou, Li Chen

bioRxiv : the preprint server for biology

|March 31, 2025

概括

检查点激酶2 (Chek2) 驱动着质瘤对CD8+T细胞的抗性. 针对Chek2-YBX1-YBX3蛋白质枢纽,与免疫检查点封锁相结合时,可以增强抗瘤免疫力和生存能力.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

质母细胞瘤 (GBM) 呈现出一种免疫抑制性瘤微环境,阻碍了CD8+ T细胞介导的杀死.
检查点激酶2 (Chek2) 之前被确定为GBM抵抗CD8+T细胞攻击的关键因素.

研究的目的:

为了阐明Chek2在质瘤中的免疫抑制作用.
为了确定Chek2有助于瘤免疫逃避的分子机制.

主要方法:

免疫沉质谱和蛋白质组学用于识别Chek2相互作用蛋白.
单基因淘汰/过度表达研究,RNA测序和ChIP测序来分析基因调节.
在体内使用YBX1抑制剂 (SU056) 结合免疫检查点阻塞 (ICB) 的研究.

主要成果:

切克2与YBX1和YBX3形成复合体,抑制促炎基因.
这些枢纽蛋白相互调节对方的表达.
针对CHK2-YBX1&YBX3枢纽,通过SU056增强抗原呈现和CD8+T细胞增殖.
组合疗法在临床前质瘤模型中显著改善了生存率.

结论:

揭示了一种由质瘤中CHK2-YBX1&YBX3蛋白中心介导的新型免疫抑制机制.
针对这个枢纽与ICB相结合,代表了对质瘤的有希望的治疗策略.

更多相关视频

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...